Skip to content
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
LinKinVax et Gustave Roussy collaborent pour mener une étude clinique HPV.DCVax de phase I/IIa pour le traitement de patients atteints d’un cancer oropharyngé associé au papillomavirus humain (HPV)
19 January 2023
Télécharger le communiqué de presse